249 related articles for article (PubMed ID: 32218358)
1. Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.
Martínez R; Geronimo BD; Pastor M; Zapico JM; Coderch C; Panchuk R; Skorokhyd N; Maslyk M; Ramos A; de Pascual-Teresa B
Molecules; 2020 Mar; 25(7):. PubMed ID: 32218358
[TBL] [Abstract][Full Text] [Related]
2. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks.
Schneider CC; Hessenauer A; Götz C; Montenarh M
Oncol Rep; 2009 Jun; 21(6):1593-7. PubMed ID: 19424641
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
4. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
Pucko E; Ostrowski R; Matyja E
Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
[TBL] [Abstract][Full Text] [Related]
5. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
[TBL] [Abstract][Full Text] [Related]
7. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
8. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
9. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
10. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1
Chojnacki K; Wińska P; Karatsai O; Koronkiewicz M; Milner-Krawczyk M; Wielechowska M; Rędowicz MJ; Bretner M; Borowiecki P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200807
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
[TBL] [Abstract][Full Text] [Related]
13. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
14. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M
Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
17. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]